All companies
Visit website
NEXTLEAP COLD SORE CARE
OperatingSkinStasis LLC
Healthcare · Founded 2022
Breakthrough treatment for cold sores-return to normal in 1-2 days
Valuation cap ⓘ
$1.2M
As of Apr 2024 · from NEXTLEAP COLD SORE CARE Convertible Note 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$106,800
Across 1 round since 2024
Latest share price
$1.00
NEXTLEAP COLD SORE CARE Convertible Note 1 offering price
Financials
FY2021–FY2024 · from SEC filings · hover any figure for its source$0
2021
$753
−$78K
2022
$33K
−$139K
2023
$60K
−$227K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$0
$753
$32,575
$59,544
Cost of goods sold
$0
$84
$4,292
$7,847
Gross margin
—
89%
87%
87%
Net income
$0
-$78,378
-$139,429
-$227,072
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$0
$16,118
$3,272
$40,511
Accounts receivable
$0
$0
$0
$0
Total assets
$0
$84,384
$109,498
$157,482
Short-term debt
$0
$161,762
$1,262
$126,318
Long-term debt
$0
$0
$0
$0
Total liabilities
$0
$161,762
$1,262
$126,318
Other
Headcount
—
0
—
0
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$1.2M
Valuation cap
NEXTLEAP COLD SORE CARE Convertible Note 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $106.8K / $1.2MInvestors 26Valuation cap $1.2M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 3 annual reports (FY2023–FY2025)
26 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0002009974Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.